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Abstract
Background: In view of the current widespread use of and reliance on a single schistosomicide, praziquantel, there is a
pressing need to discover and develop alternative drugs for schistosomiasis. One approach to this is to develop High
Throughput in vitro whole organism screens (HTS) to identify hits amongst large compound libraries.
Methodology/Principal Findings: We have been carrying out low throughput (24-well plate) in vitro testing based on
microscopic evaluation of killing of ex-vivo adult S. mansoni worms using selected compound collections mainly provided
through the WHO-TDR Helminth Drug Initiative. To increase throughput, we introduced a similar but higher throughput 96-
well primary in vitro assay using the schistosomula stage which can be readily produced in vitro in large quantities. In
addition to morphological readout of viability we have investigated using fluorometric determination of the reduction of
Alamar blue (AB), a redox indicator of enzyme activity widely used in whole organism screening. A panel of 7 known
schistosome active compounds including praziquantel, produced diverse effects on larval morphology within 3 days of
culture although only two induced marked larval death within 7 days. The AB assay was very effective in detecting these
lethal compounds but proved more inconsistent in detecting compounds which damaged but did not kill. The utility of the
AB assay in detecting compounds which cause severe morbidity and/or death of schistosomula was confirmed in testing a
panel of compounds previously selected in library screening as having activity against the adult worms. Furthermore, in
prospective library screening, the AB assay was able to detect all compounds which induced killing and also the majority of
compounds designated as hits based on morphological changes.
Conclusion: We conclude that an HTS combining AB readout and image-based analysis would provide an efficient and
stringent primary assay for schistosome drug discovery.
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Introduction
Schistosomiasis is the most important helminth infection and
the second most important parasitic disease next to malaria. It
continues to spread in parts of the world due to water management
and irrigation projects [1]. The major current strategy for control
of schistosomiasis is chemotherapy and significant reductions in
prevalence of infection and of severe disease have been achieved in
several parts of the world e.g. Central and South America, North
Africa and China [2]. A common approach is to treat all school-
aged children in areas where the prevalence of schistosomiasis is
over 10% and the whole community when the prevalence is over
50%. Such control has now been extended to several African
countries through the Schistosomiasis Control Programme funded
by the Bill and Melinda Gates Foundation and this has led to
significant reductions in the prevalence, intensity and morbidity of
infection [3]. However, chemotherapy does not interrupt trans-
mission and so for this morbidity reduction to be maintained
repeated periodic treatment will need to be continued for the
foreseeable future.
Since its introduction in the 1980s praziquantel (BiltricideH)
has been the mainstay of control programmes and it is now the
only drug being used for mass treatment of schistosomiasis. It is
an effective drug with broad spectrum activity against all five
human schistosome species, low toxicity, few side-effects, simple
administration and currently low cost. In mass treatment
campaigns at a dose of 40 mg/kg praziquantel usually results in
parasitological cure rates of around 70% and egg count reduction
rates of more than 90% [4]. The marked increase in use of, and
reliance on, repeated treatments with praziquantel has raised
concerns about the possible emergence of drug resistance which,
if it were to occur, would leave us without an effective
schistosomicide [5]. There have been sporadic reports of low
efficacy and of treatment failure in individuals from different
parts of the world but as yet no convincing evidence of
development and selection of resistance in endemic areas.
However, strains of schistosomes which have been isolated from
drug treatment failures show lower susceptibility to praziquantel
and strains with stable elevated tolerance to the drug can be
selected in the laboratory [6].
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possibility of the emergence of drug resistance led to the
establishment of the ‘‘Helminth Drug Initiative (HDI)’’ (http://
apps.who.int/tdr/svc/research/lead-discovery-drugs/workplans/
helminth-drug-initiative) by the WHO Special Programme for
Research and Training in Tropical Diseases (TDR) for the
discovery of new schistosomicides [7]. As part of the HDI, whole
organism screening was established with the London School of
Hygiene and Tropical Medicine chosen as one of the screening
centers. The screen adopted involved culture of adult worms with
test compounds for 5 days with activity being determined by
microscopic examination of worm death [8]. The HDI was
initially based on highly selected libraries and throughput was not
then the major consideration. However, with the provision of
larger compound sets we implemented a 96 well microplate
primary screen using in vitro derived schistosomula which allows
markedly higher throughput than the adult worm-based assay. A
similar assay was recently described by Abdulla et al [9]. Such
assays are limited by the need for manual microscopic reading
and, in order to develop a High Throughput Screen (HTS), the
assay needs to be automated [10]. Therefore, alongside testing the
use of High Content Screening (HCS) to allow automatic image
analysis, we have investigated the use of a plate-based assay using
Alamar Blue (AB), a redox indicator of enzyme activity which has
been successfully used for colorimetric or fluorometric determina-
tion of viability of a number of protozoan parasites in whole
organism drug screening e.g. African trypanosomes and Leishmania
[11–12]. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazo-
lium bromide) which is also an indicator of enzyme activity has
previously been shown to be reduced by adult schistosomes in vitro
and used as a measure of parasite viability [13]. AB has the
advantage over MTT in that it is non-toxic and so can be used to
monitor effects over time.
We report here our results on the development and validation of
the AB assay compared with morphology-based (microscopic)
assessment of compound activity. For this purpose we have tested:
(i) Several compounds (referred to here as ‘‘Standards’’) with
proven activity against schistosomes in vivo either in humans
(oxamniquine [OX] [14]; praziquantel [PZ] [15]; methyl-
clonazepam [MCZ] [16]; oltipraz [OPZ] [17]), in sub-human
primates (Ro15-5458 [Ro15] [18]) or at least in mice (dihydroar-
temisinin [DHA] [19] [the analogue, artemether, has also been
shown to be active in humans [20]]; clonazepam [CZ] [21]). In
addition to their proven efficacy in vivo these Standard compounds
were chosen because we had shown them to have a range of effects
and speed of action against adult worms and schistosomula in vitro.
Thus, PZ, MCZ, CZ and OPZ readily kill adult worms in vitro and
have IC50s of 0.36, 0.37, 1.42, and 1.25 mg/ml, respectively
(unpublished observations). However, OX, Ro15 and DHA have
IC50s .10 mg/ml, the maximum concentration we use in our
primary adult worm screening for WHO-TDR [8]; (ii) A panel of
compounds found to be active or inactive by the adult worm assay
during prior routine adult worm screening of compound libraries
mostly supplied through the HDI (WHO-TDR); (iii) A subsample
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Production of schistosomula
Cercariae of the Puerto Rican strain of Schistosoma mansoni [22]
were shed in clean tap water from infected Biomphalaria glabrata
snails exposed to direct illumination for 1 h. The cercariae were
concentrated to 20 ml using an 8 mM filter (Sartorius CN,
Scientific Laboratory Supplies, Ltd) on a concentration apparatus
(Millipore) and cooled on ice for 30 min. The water was carefully
removed from the pelleted cercariae and replaced by cold serum
free medium 169 [23] (M169) supplemented with 300 U/ml
Penicillin (Gibco, UK), 300 mg/ml Streptomycin (Gibco, UK),
and 160 mg/mL Gentamicin (Sigma, UK) (Incomplete M169).
Under sterile conditions, cercariae were mechanically transformed
into schistosomula using the ‘Syringe Method’ [24]. The cercarial
head and tail suspension was layered onto a sterile gradient of 50%
and 60% Percoll (Sigma, UK) in M169 in 15 ml polystyrene tubes
[25]. The tubes were spun for 10 min at 3506 g at 4uC. After
centrifugation each of the layers was carefully removed and the
cercarial heads (schistosomula) recovered from the 60% layer,
washed twice in 20–25 ml of Incomplete M169 by centrifuging at
4006 g and 4uC for 2 min. The schistosomula were washed in
M169 supplemented with 100 U/ml Penicillin, 100 mg/ml
Streptomycin and 5% foetal calf serum (Sigma, UK) (Complete
M169, cM169). They were then transferred into 6-well plates,
incubated overnight at 37uC and 5% CO2 and checked for high
viability (#2% dead or damaged larvae) prior to use in screening.
Drug sensitivity assay
Standard drugs: PZ, CZ and DHA were from Sigma, UK;
MCZ and Ro15 were a kind gift from Dr H. Stohler (Hoffman-La
Roche, Basle, Switzerland); OX was from Pfizer Ltd. Sandwich,
UK; OPZ was provided by WHO-TDR, Geneva, Switzerland.
These were dissolved in dimethylsulphoxide (DMSO) (Sigma,
UK). Test compounds: these were from a number of different
compound collections provided by WHO-TDR for routine
screening using the adult worm assay. Since this is carried out at
up to 10 mg/ml or (when compounds of known molarity are
provided) at 12.5 mM, stock solutions of 10 mg/ml or 12.5 mM in
DMSO were used. Mid-dilutions were performed as necessary in
Author Summary
Only one drug, praziquantel, is widely available for treating
schistosomiasis, a disease affecting an estimated 200
million people. Because of increasing usage there is
concern about development of praziquantel drug resis-
tance and a perceived need to develop new schistosomi-
cides. Possible sources of these are large collections of
compounds held by pharmaceutical companies and
academic institutions. Anti-schistosome activity can be
detected in vitro by visually assessing damage to cultured
adult schistosome worms, but these are large and are
recovered from mice which somewhat limits screening
throughput. By contrast, schistosomula can be produced
in vitro and used for screening in microwell plates, thus
allowing medium throughput screening. High throughput
screening (HTS) would require automated readout of
schistosomulicidal action rather than manual microscopy.
Here we report on the use of Alamar blue (AB), a
fluorescent indicator of cell viability which can be
measured rapidly and automatically. The AB assay was
readily able to detect compounds causing death or severe
damage to the larvae but was less reliable than
microscopy for more subtle morphological changes
including those induced by some known schistosome
drugs. It is concluded that an automated HTS would
benefit from integrated use of both AB and automatic
image-based morphology assays.
Schistosome Drug Screening Assay
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plates (Nunc, UK). Finally, 100 schistosomula were added in
100 ml of cM169 to each well. Negative control wells contained
schistosomula cultured in either cM169 medium or 0.5% DMSO
in cM169. The final concentration of 0.5% DMSO did not affect
the larvae within the culture periods used.
Experiments with standard drugs were carried out in triplicate
wells. The compounds were tested at 10 mg/ml (i.e. 28, 32, 30, 44,
32, 38, 35 mM for OX, PZ, MCZ, OPZ, CZ, Ro15 and DHA,
respectively) or 1 mg/ml (i.e. 2.8–4.4 mM).
Microscopic assessment of schistosomula viability
Viability of schistosomula was assessed on days 1, 3, 5 and 7 and
in some experiments on day 14 using an inverted microscope
(Leitz Diavert Wetzlar, Germany). Drug effects were determined
by recording all schistosomula in each well as unaffected, dead
(immotile, often showing a characteristic uniform shape and
granular appearance) or morphologically damaged (showing a
range of altered shapes, granularity and/or blebbing but still with
some motility).
Alamar blue assay
20 ml of Alamar Blue (AbD Serotec, UK) was added to each well
and the plates incubated at 37uCa n d5 %C O 2 for 24 h unless
otherwise stated. The fluorescence intensity was measured using a
Spectramax Gemini plate reader (Molecular Devices) using an
excitation wavelength of 530 nm and an emission wavelength of
580 nm.
Statistical analysis
Prism 4 (GraphPad Software, Inc) was used for graph drawing
and statistical analysis. Student’ t test was used to determine the
significance of differences between mean values.
Results
Alamar blue reduction by S. mansoni schistosomula
An initial experiment showed that AB could readily detect
metabolic activity during schistosomula culture. As shown in
Figure 1 there was induction of significant (P,0.01) fluorescence
as early as 1 h following incubation with 1000 schistosomula (5000/
ml). By 3 hrs significant levels of fluorescence were seen with both
100 and 1000 schistosomula and this was significantly enhanced
(P,0.001) at 24 h (4 and 25 fold higher fluorescence levels,
respectively, for 100 and 1000 schistosomula compared with control
without parasites). At each time point 1000 schistosomula induced
significantly greater fluorescence than 100 (at 1 and 3 h P,0.01; at
24 h P,0.0001) but use of such high numbers of larvae for
screening would greatly reduce possible throughput. Based on such
data, future experiments with AB used 100 schistosomula per well
read at 24 h or later. In preliminary experiments we showed that
OPZ, which kills schistosomula in vitro, inhibited this AB conversion
and so we were encouraged to test the assay further.
Comparison of Microscopy-based and Alamar blue assays
using known schistosome active compounds (standards)
Microscopy-based assay (morphological observa-
tions). Using 10 mg/ml (Figure 2A) only CZ and OPZ caused
elevated larval killing over the time course, increasing from day 3
to day 7 when 54% and 80% killing was observed, respectively.
However, all of the Standards induced marked morphological
changes (damage) to the larvae. By day 1 90–100% of larvae
treated with PZ, MCZ or CZ showed damage or death and by day
3 all Standards induced .75% damage or death. By comparison
1 mg/ml (Figure 2B) induced very little larval death at any time
point but OX, PZ, MCZ and OPZ caused .75% damage on days
3–7 whereas CZ, Ro15 and DHA failed to induce morphological
changes at any time-point. Such experiments with the Standard
drugs have been reproduced many times and in view of this and our
experience using the larval assay in primary compound screening
we routinely read the microscopy assay at day 3 and define a hit as
causing $70% damage or death.
Alamar blue assay. Graphs of the AB results for the
Standards are also shown in Figure 2. For comparative purposes
the dotted horizontal lines on these graphs represent AB values
25% lower than the mean value for the DMSO control wells. The
choice of 25% inhibition is based on overview of all of the results
from these studies and represents a value which appears to be a
useful cut-off for establishing hits based on drug-induced inhibition
of metabolism (i.e. lower AB fluorescence values).
Using 10 mg/ml of the Standards (Figure 2A) there was little
effect by day 1. By day 3 Ro15, OPZ and DHA had inhibited AB
values by .25% compared with controls. On day 5 OPZ and
DHA showed .50% inhibition, MCZ and Ro15 were close to
50% and PZ and CZ were close to the 25% level although some
wells showed ,25% inhibition. By day 7 all of the drugs apart
from OX resulted in AB inhibition of .25%. When tested at mg/
ml (Figure 2B) only PZ and OPZ showed inhibition .25% by day
7. Extending the culture period to 14 days and also increasing the
AB reading times to +48, +72 and +96 h did not enhance the
discrimination between controls and these Standards (data not
shown) and so culture for 7 days was considered to be the optimal
duration for this assay with .25% AB inhibition as the cut-off.
Comparison of Microscopy-based and Alamar blue assays
using compounds active against the adult worms in vitro
We next tested the larval assay against a random collection of 33
compounds which had proved to be active in vitro at 10 mg/ml
Figure 1. Alamar blue fluorescence development following
culture with schistosomula. Wells contained 0, 100 (500/ml) or 1000
(5000/ml) schistosomula. # Wells containing schistosomula but no Alamar
blue at time 0 (these values did not alter with time in culture). * P,0.01,
** P,0.0001 relative to wells with no schistosomula added. The mean 6
standard deviation of fluorescence, expressed in arbitrary units (AU), is
based on 5 replicate wells.
doi:10.1371/journal.pntd.0000795.g001
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www.plosntds.org 3 August 2010 | Volume 4 | Issue 8 | e795Figure 2. Comparison of microscopy and Alamar blue to assess activity of known anti-schistosome drugs. Replicate 96-well microtitre
plates were set up containing DMSO at 0.5% and either 10 mg/ml (Figure A) or 1 mg/ml (Figure B) of Oxamniquine (OX), Praziquantel (PZ),
Meclonazepam (MCZ), Clonazepam (CZ), Ro15-5458 (Ro15), Oltipraz (OPZ) or Dihydroartemisisin (DHA). 100 schistosomula were added per well.
Triplicate wells were set up for each treatment. The % dead or damaged schistosomula were counted on each of days 1, 3, 5 and 7. Alamar blue was
added on these days and fluorescence read in Arbitrary Units (AU) 24 h later. Mean fluorescence values from wells containing AB and cM169 without
Schistosome Drug Screening Assay
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+ve’’) along with 30 randomly selected adult negative compounds
(‘‘Adult 2ve’’).
Microscopy-based assay (morphological observations).
Figure 3A shows the results using 10 mg/ml of these
compounds. 10/33 (30%) of Adult +ves had killed all or nearly
all the larvae by day 1 and 80% were classified as hits ($70%
damaged or dead). By day 3, 28/33 (85%) had induced killing of
most larvae and all were detected as hits. Larval death increased at
days 5 and 7 at which time all of the compounds caused .50%
death and all but 4 induced 100% parasite death.
Using 1 mg/ml (Figure 3B) only 14/33 (42%) would have been
classified as hits on morphological grounds on days 3, 5 and 7.
None of the Adult 2ves induced significant parasite death at
either drug concentration and by day 3 only two were classed as
hits based on morphological damage when tested at 10 mg/ml,
giving a false positive rate of ,7% (NB ‘‘false positive’’ is used here
to define activity relative to the adult assay. The latter is taken as
the reference because it is used as the secondary and definitive
screen for hit progression. Activity in the larval but not the adult
screen may be due to higher sensitivity of the schistosomula or to
larval specific action). At 1 mg/ml there were no false positives
amongst the Adult 2ves.
Alamar blue assay. Figure 3A shows the results using
10 mg/ml. Following addition of AB on day 1, all 10 of the
Adult +ve compounds which had resulted in visible larval death at
this time induced AB inhibition of $25%. Overall the assay
detected 16/33 (48%) as hits ($25% AB inhibition) compared
with the 80% detected visually. By day 3 all of the Adult +ves had
induced AB inhibition of $25% although some values were only
just below the 25% level. By days 5 and 7 all Adult +ves caused
inhibition of AB reduction of .50% compared with controls.
However, 12/30 of the Adult 2ves also gave Alamar blue
inhibition of $25% at day 7 (i.e. a false positive rate of 40%). The
range of AB values observed with the Adult 2ves reflects
compound-specific effects rather than random variation between
wells e.g. numbers of larvae per well, since when compounds were
tested in duplicate there was a highly significant correlation
between paired observations (P,0.0001) (data not shown).
Using 1 mg/ml (Figure 3B) 22/33 (67%) Adult +ves gave AB
inhibition of $25% at day 7 and there was only one false positive
(AB inhibition $25%) amongst the Adult 2ves (3%).
Taking the results with the Standards and the Adult +ves
together, the 3 day morphology-based assay detected all of these as
hits at 10 mg/ml whereas testing at 1 mg/ml resulted in a failure to
detect 3/7 of the Standards and 58% of the Adult +ves. The day 7
AB assay was also effective in detecting the Standards (apart from
OX) and the Adult +ves at 10 mg/ml but gave a high false positive
rate (40%) with the Adult 2ves. At 1 mg/ml the AB assay failed to
detect 5/7 of the Standards.
Comparison of the Microscopy-based and AB assays
during routine primary screening
In the following experiment we compared the 3 day microscopy
and 7 day AB assays during primary screening of 558 compounds.
These were from a compound library provided by WHO-TDR at
known molarity in which circumstance primary screens are run at
12.5 mM. As shown in Figure 4, the visual assay detected 8
compounds lethal to the larvae and 27 designated as hits based on
damage i.e. a total of 35 ‘‘hits’’ (,6% hit rate). The AB assay
readily detected all 8 of the drugs causing larval death and 21/27
(78%) of the morphologically damaged hits. In addition there were
27/558 compounds causing $25% inhibition in the AB assay
which were not detected as hits by morphology. Overall, therefore,
56/558 compounds induced AB inhibition of $25% i.e. a hit rate
of 10%.
The 35 visual hits were tested in the secondary ex-vivo adult
assay and 5 were shown to be positive. All of these were in the
group of 8 compounds which had resulted in schistosomula death
by day 3 and which also caused marked inhibition of AB
fluorescence at day 7. Of the 35 visual hits 6 caused crystal
formation/drug deposition in or on the parasites and in some cases
this seems to pierce the larvae e.g. Figure 5. Such effects are not
uncommon and assessment of the morphological condition of the
larvae can be difficult in such cultures. None of the 6 were hits in
the adult assay and two of them gave the highest AB AU
fluorescence values in Figure 4 indicating that the larvae were still
highly metabolically active.
Discussion
Abdulla et al [9] recently described a medium throughput drug
screen based on microscopically determined morphological
changes to schistosomula. It was reported that attempts to
quantitate cell death in schistosomula using nuclear dyes did not
correlate with observed morphological effects seen under bright
field microscopy. Our experience supports the conclusion that
morphological changes to schistosomula represent a rapid and
sensitive means of detecting anti-schistosome activity. An assay
based on inhibition of AB reduction was also very effective in
detecting severely damaged and dead schistosomula and with a
sufficiently long culture period (7 days) was able to detect most of
the known schistosome active compounds tested.
The microscopy-based morphological assay described by
Abdulla et al [9] involved a primary schistosomula screen at 7
days, a secondary similar screen at 24 h to detect fast-acting
compounds and then a tertiary screen using ex vivo adults read at
day 1–4. Priority for progression to the adult screen was based on
activity against schistosomula at 24 h. Based on initial screening of
two commercially obtained compound collections it was conclud-
ed that the hit rates of 25 and 15% when screening was at 10 and
5 mM were too high whereas the hit rate of 10% at 1 mM was
acceptable. In our experiments with a range of known schistosome
active drugs (Standards) we found that the microscopy-based larval
screen described here, which is standardly read at day 3, detected
all 7 compounds as hits when tested at 10 mg/ml (i.e. 28–44 mM)
but at 1 mg/ml (i.e. 2.8–4.4 mM) CZ, Ro15 and DHA were not
detected even at 7 days. The failure to detect Ro15 and DHA at
1 mg/ml may be seen as a failure of the assay but in practice these
two compounds would not have been detected in our secondary
adult worm screen since they are inactive against the adult worms
in vitro at 10 mg/ml. In our testing of a collection of 33 compounds
originally detected as hits by primary screening against adult
worms, all were detected at 10 mg/ml, but at 1 mg/ml 58% were
not detected even when cultured up to 7 days. We conclude that
testing at 1 mg/ml (estimated at ,3 mM) missed an unacceptable
percentage of the Adult +ves. As mentioned above the choice of
1 mM in the earlier report [9] was an empirical one based on
parasites were subtracted from the values for test wells. The results for each of the triplicate wells are shown in the graphs with the horizontal bars
representing the mean values. The dotted horizontal line on each AB graph corresponds to an AU value 25% lower than the mean for the triplicate
DMSO controls. Values for medium alone controls were very comparable to the DMSO values (data not shown).
doi:10.1371/journal.pntd.0000795.g002
Schistosome Drug Screening Assay
www.plosntds.org 5 August 2010 | Volume 4 | Issue 8 | e795Figure 3. Comparison of microscopy and Alamar blue to assess activity of compounds previously screened as active or inactive
against adult schistosomes in vitro. See Legend to Figure 2 for most details. A: 10 mg/ml, B: 1 mg/ml. ‘‘Adult +ves’’: 33 compounds previously
found to be lethal to adult worms in vitro. ‘‘Adult 2ves’’: 30 compounds found to be inactive against adult worms in vitro.
doi:10.1371/journal.pntd.0000795.g003
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found that a selection of Adult 2ve compounds from the
collections which yielded the Adult +ves gave a low false positive
rate of ,7% at 10 mg/ml. Since these Adult 2ves were randomly
selected from the libraries this value of 7% represents the hit rate
which would be expected from these collections using the larval
assay at 10 mg/ml. However, in our prospective screening of new
collections of compounds using the schistosomula primary screen
at 10 mg/ml hit rates up to 16% have been obtained whilst with
compounds tested at 12.5 mM we have found an average of 6%
hits. Given the variation in hit rates seen with different libraries,
the rational approach is to determine a concentration that gives an
acceptable hit rate for progression to secondary screening [9].
It is interesting that all of the compounds we tested here which
had been found to be active in the adult worm screening of WHO-
TDR collections proved to be highly active against the
schistosomula as judged visually. Thus of 38 such adult actives
tested all but 5 had killed .75% of larvae and all had caused
$70% morphological damage by day 3. By contrast the Standards
produced more diverse effects, readily detectable by morpholog-
ical damage but, with the exception of OPZ, not resulting in high
levels of parasite death up to a week in culture.
AB fluorescence was found to be a reliable indicator of
schistosomula viability and the AB assay was able to detect
severely damaging and lethal effects caused by test compounds.
However, it was much less effective in detecting the more subtle
morphological effects such as those caused by most of the
Standards. For example, OPZ which kills around 75% of larvae
by day 7 in culture at 10 mg/ml was reliably detected as causing
.25% inhibition of AB conversion from day 3 onwards, reaching
100% inhibition by day 7. On the other hand PZ, MCZ, CZ and
Ro15 which damage all but kill few schistosomula within 7 days
had more modest effects on AB conversion although, if cultured up
to 7 days, $25% inhibition was generally observed. However,
having run these Standards as controls in many screens we have
noted that occasionally these four compounds fail to show a $25%
inhibition and so would not be detected as hits. Altering test
compound concentrations, culture duration and interval to AB
reading did not lead to a protocol which improved this. We
conclude that relative to microscopy the AB assay would
occasionally miss detecting PZ, Ro11, CZ and Ro15 and would
not detect OX. It is, however, worth noting that neither Ro15 nor
OX are active in the adult in vitro visual assay and so would not be
taken forward as hits following secondary screening.
Comparison of the morphology and Alamar blue assays against
collections of compounds previously shown to be positive or
negative against adult worms in vitro showed that both assays were
100% sensitive in detecting the Adult +ves at 10 mg/ml. However,
whereas the microscopy assay was positive for only ,7% of Adult
2ve compounds from these source libraries, the AB assay
produced a wide range of values with 40% of these falling below
the cut-off for hits in this assay. When the Adult 2ves were tested
at 1 mg/ml the AB assay showed only 3% as hits and also showed a
somewhat higher sensitivity in detecting Adult +ves (67%) than the
morphology assay (42%). Since the Adult 2ve compounds were
randomly chosen from compound collections sent for testing, the
40% and 3% ‘‘hit’’ rates with 10 and 1 mg/ml, respectively, reflect
the hit rates which would be obtained if the AB assay were used for
primary screening of these collections. As discussed above the
optimal concentration for a particular library would need to be
chosen empirically. So, for AB screening of this particular
compound collection the appropriate concentration would be
somewhere between 10 and 1 mg/ml in order to yield a
manageable hit rate for progression to the adult worm secondary
screen. Notably, in this retrospective testing of the Adult +ves at 1
or 10 mg/ml, all wells, apart from 2 on Day 1, where there was
larval death (range 10–100% cf controls 0.2–2%), the AB values
were .25% lower than the controls and in most instances .50%
lower. Similarly, in the prospective testing at 12.5 mM (Figure 4)
all wells in which larval death was recorded (37–100% death) were
readily detected by the AB assay.
In conclusion the AB assay has proved to be very effective in
detecting compounds which have severe effects on the larvae
resulting in a proportion of the larvae dying. The assay is also very
suitable for HTS automation and is valuable when there is crystal
formation on the parasites which obscures accurate observation.
However, it showed somewhat lower sensitivity and reliability
compared with manual visualization in detecting the more subtle
damage caused by some known anti-schistosome compounds
Figure 4. Comparison of microscopy and Alamar blue assays
during routine screening. See Legend to Figure 2 for most details.
Results are shown for the screening of 558 compounds (i) by
microscopy at day 3 of culture, larvae being reported as DEAD,
morphologically DAMAGED or NORMAL and (ii) by addition of Alamar
blue on day 7 and reading 24 h later.
doi:10.1371/journal.pntd.0000795.g004
Figure 5. ‘‘Crystal-like’’ formation on schistosomula. An example
of crystal-like deposit from one of the wells containing schistosomula
categorized as DAMAGED from Figure 4. (Magnification 6100). Image
captured using a Leitz DMRB microscope (Leica, Germany) with
attached Leica DFC 420 digital camera controlled by Leica Application
Suite version 3.1 software (Leica Microsystems [Switzerland] Ltd.).
doi:10.1371/journal.pntd.0000795.g005
Schistosome Drug Screening Assay
www.plosntds.org 7 August 2010 | Volume 4 | Issue 8 | e795including praziquantel. Therefore, we envisage an HTS may
usefully incorporate both AB and image-based analysis and are
currently investigating if automatic HCS image-based analysis can
be developed which has comparable sensitivity to the manual
visualization assay.
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